【摘要】 目的探讨伊立替康(开普拓,IRI,CPT-11)联合氟尿嘧啶(5-Fu)、甲酰四氢叶酸(CF)一线治疗进展期胃癌的疗效及毒性作用。方法对2006年6月至2008年12月采用该方案治疗的进展期胃癌36例患者进行回顾性分析,每例患者至少接受6个周期化疗。用法:CPT-11180mg/m2,静脉滴注30～90min,第1天;CF400mg/m2,静脉滴注2h,第1天;5-Fu400mg/m2,继CF后静脉推注,然后2400mg/m2,持续静脉滴注,46h,第1天,14d为1个周期。每3～4个周期后按照RECIST实体瘤近期客观疗效评定标准进行疗效评价。结果CR2例,占5.6%;PR14例,占38.9%;SD9例,占25.0%;PD11例,占30.6%;客观有效率(CR+PR)为44.4%;临床获益率(PR+CR+SD)为69.4%,中位疾病进展时间(TTP)5.9个月;中位生存期(MST)10.1个月。不良反应主要为骨髓抑制、延迟性腹泻。结论FOLFIRI方案一线治疗进展期胃癌,疗效较好,毒副反应可耐受,值得临床进一步应用与推广。更多还原

【Abstract】 Objective To observe the efficacy and safety of FOLFIRI regimen in first-line treatment fo patients with advanced gastric cancer.Methods Thirty-six patients with advanced gastric cancer treated with FOLFIRI regimen form June 2006 to Dec were reviewed and analyzed.All patients received at least 6 cycles of chemotherapy.The regimen included irinotecon(CPT-11) 180 mg/m2 d1,iv dripping in 30-90 minutes;leucovorin(CF) 400 mg/m2 iv infusion over 2 hours on day 1;fluorouracil 400 mg/m2 iv bolus on day 1,then 2400 mg/m2 iv infusion over 46 hours.The regimen was repeated every 14 days.The patients were assessed on the basis of Response Evaluation Criteria in Solid Tumors(RECIST) after 3-4 cycles.Results Thirty-six patients were assessable for the efficacy and safety.Of them,2 had complete response;14 had partial response;9 had stable disease and 11 had progression disease.The over-all response rate of the whole group was 44.4%(16 /36) ;clinical tumor control rate was 69.4%(27 /36).Median time to progression(TTP) was 5.9 months and median survival time(MST) was 10.1 months.The main toxic reactions were myelosuppression and tardive diarrhoea.Conclusions FOLFIRI regimen is effective and well tolerable in the-first-line treatment for advanced gastric cancer,and is worth of use and wide spread.更多还原